Skip to main content
Premium Trial:

Request an Annual Quote

Bruce Alberts, John St. Amand

Premium
Bruce Alberts has been named as new editor-in-chief of Science. Alberts, who is president emeritus of the US National Academy of Sciences and a professor of biochemistry and biophysics at the University of California, San Francisco, will start his new appointment on March 1, 2008.
 
Alberts will succeed Donald Kennedy, president emeritus of Stanford University, who has been Science’s editor-in-chief since 2000. Alberts holds a PhD from Harvard University. After spending 10 years on the faculty of Princeton University, he moved to UCSF, where he later became chair. He is one of the original authors of The Molecular Biology of the Cell, a leading textbook.
 

 
John St. Amand has joined Highland Capital Partners as a venture partner, the company said last week. He is the founder and former CEO of Telica, a Highland-backed company. St. Amand holds a BSEE from the University of Massachusetts at Amherst and an MSEE from Northeastern University. Highland Capital Partners is an investor of Helicos BioSciences.

 
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.